Marcy l'Etoile - 05/25/2006. bioMérieux, a global leader in the field of in vitro diagnostics, today announced that it has signed an agreement to sell its hemostasis range of products to Trinity Biotech plc.
The company’s hemostasis line includes the MDA®, MTX® and Thrombolyzer® platforms, as well as a comprehensive menu of reagents to analyze blood clotting parameters. With quality products, bioMérieux ranks fourth in the global hemostasis market, achieving €45 million sales in 2005.
The transaction is perfectly aligned with the company’s strategic commitment to focusing on
operations related to infectious diseases, cancer and cardiovascular diseases as well as to industrial applications.
For bioMérieux, the total value of the deal could amount to nearly $60 million, including the proceeds from assets sold, receivables to be collected and $5.5 million of the transaction contingent on meeting the business’ 2006 objectives. bioMérieux will manufacture the products on behalf of Trinity Biotech plc for a 12 month transitory period. The capital gain should cover the related restructuring expense and the remaining fixed costs.
“ Trinity Biotech is a leading provider of hemostasis solutions,” said bioMérieux Executive Vice President Benoît Adelus, “ and we are very pleased that this agreement will allow our customers to continue to enjoy high-quality service. It will also enable bioMérieux to consolidate its expansion around its strategic product ranges.”
The deal is expected to close before June 30.